(Stroke. 2000;31:1829.)
© 2000 American Heart Association, Inc.
Original Contributions |
Fluoxetine in Early Poststroke Depression
A Double-Blind Placebo-Controlled Study
From Tour de Gassies, Neurorehabilitation Unit, Bruges, France.
Correspondence to Laurent Wiart, MD, Tour de Gassies, Neurorehabilitation Unit, 33520 Bruges, France. E-mail Wiartl{at}aol.com
Background and Purpose—Early poststroke depression (PSD) is a frequent and specific entity that impairs the rehabilitation and functional recovery of hemiplegic patients. This trial was designed to study the efficacy and tolerance of fluoxetine (FLX) in the treatment of early PSD.
Methods—This was a multicenter, double-blind, placebo-controlled study. Recent hemiplegic patients (<3 months) suffering from major depressive disorder (determined by International Classification of Diseases, 10th Revision, and Montgomery-Asberg Depression Rating Scale [MADRS] >19) were randomized to receive either 20 mg/d fluoxetine (FLX) or placebo for 6 weeks. Patients were evaluated by use of the Motricity Index, Mini-Mental State Examination, Functional Independence Measure, and MADRS. Statistical analysis was performed by using an intent-to-treat approach comparing the 2 groups at day 0 (baseline) and days 15, 30, and 45 (end point).
Results—Of 121 patients screened, 31 were included in the study, 16 in the FLX group and 15 in the placebo group. There were no significant differences in baseline characteristics among the 2 groups. The FLX-treated patients compared with placebo-treated patients demonstrated significant improvement in mean MADRS scores at end point (11.8±6.7 [mean±SD] versus 18.7±10.0, respectively; P=0.05). FLX-treated patients compared with placebo-treated patients also demonstrated greater response rate (62.5% versus 33.3%, respectively) and greater mean decrease of MADRS (16.6 versus 8.4, respectively; P=0.02). There were no differences in motor, cognitive, or functional improvement and no significant side effects after FLX treatment, except for a patient with a moderate and transient increase of transaminases.
Conclusions—FLX is an efficacious and well-tolerated treatment for early PSD. Further research is needed to evaluate the efficacy and safety of long-term treatment in this population.
Key Words: antidepressant agents • cerebrovascular disorders • depression • fluoxetine
This article has been cited by other articles:
 |
|
 |
|
  R. G. Robinson, R. E. Jorge, and K. Clarence-Smith Double-Blind Randomized Treatment of Poststroke Depression Using Nefiracetam J Neuropsychiatry Clin Neurosci, May 1, 2008; 20(2): 178 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Townend, M. Brady, and K. McLaughlan A Systematic Evaluation of the Adaptation of Depression Diagnostic Methods for Stroke Survivors Who Have Aphasia Stroke, November 1, 2007; 38(11): 3076 - 3083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ramasubbu, R. Tobias, A. M. Buchan, and N. T. Bech-Hansen Serotonin transporter gene promoter region polymorphism associated with poststroke major depression. J Neuropsychiatry Clin Neurosci, December 1, 2006; 18(1): 96 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chen, J. J Guo, S. Zhan, and N. C Patel Treatment Effects of Antidepressants in Patients with Post-Stroke Depression: A Meta-Analysis Ann. Pharmacother., December 1, 2006; 40(12): 2115 - 2122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Chen and J. J. Guo Meta-Analysis of Antidepressant Treatment for Patients With Poststroke Depression Stroke, June 1, 2006; 37(6): 1365 - 1366. [Full Text] [PDF]
|
|
|
|
|
|
S. Choi-Kwon, S. W. Han, S. U. Kwon, D.-W. Kang, J. M. Choi, and J. S. Kim Fluoxetine Treatment in Poststroke Depression, Emotional Incontinence, and Anger Proneness: A Double-Blind, Placebo-Controlled Study Stroke, January 1, 2006; 37(1): 156 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bates, J. Y. Choi, P. W. Duncan, J. J. Glasberg, G. D. Graham, R. C. Katz, K. Lamberty, D. Reker, and R. Zorowitz Veterans Affairs/Department of Defense Clinical Practice Guideline for the Management of Adult Stroke Rehabilitation Care: Executive Summary Stroke, September 1, 2005; 36(9): 2049 - 2056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Duncan, R. Zorowitz, B. Bates, J. Y. Choi, J. J. Glasberg, G. D. Graham, R. C. Katz, K. Lamberty, and D. Reker Management of Adult Stroke Rehabilitation Care: A Clinical Practice Guideline Stroke, September 1, 2005; 36(9): e100 - e143. [Full Text] [PDF]
|
|
|
|
|
|
M. L. Hackett, C. S. Anderson, and A. O. House Management of Depression After Stroke: A Systematic Review of Pharmacological Therapies Stroke, May 1, 2005; 36(5): 1092 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. C. Kales, D. F. Maixner, and A. M. Mellow Cerebrovascular Disease and Late-Life Depression Am J Geriatr Psychiatry, February 1, 2005; 13(2): 88 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J C Davies, P. R Jackson, J. Potokar, and D. J Nutt Treatment of anxiety and depressive disorders in patients with cardiovascular disease BMJ, April 17, 2004; 328(7445): 939 - 943. [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Charney, C. F. Reynolds III, L. Lewis, B. D. Lebowitz, T. Sunderland, G. S. Alexopoulos, D. G. Blazer, I. R. Katz, B. S. Meyers, P. A. Arean, et al. Depression and Bipolar Support Alliance Consensus Statement on the Unmet Needs in Diagnosis and Treatment of Mood Disorders in Late Life Arch Gen Psychiatry, July 1, 2003; 60(7): 664 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rasmussen, M. Lunde, D. L. Poulsen, K. Sorensen, S. Qvitzau, and P. Bech A Double-Blind, Placebo-Controlled Study of Sertraline in the Prevention of Depression in Stroke Patients Psychosomatics, June 1, 2003; 44(3): 216 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Huffman and T. A. Stern Acute Psychiatric Manifestations of Stroke: A Clinical Case Conference Psychosomatics, February 1, 2003; 44(1): 65 - 75. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Turner-Stokes and N. Hassan Depression after stroke: a review of the evidence base to inform the development of an integrated care pathway. Part 2: Treatment alternatives Clinical Rehabilitation, March 1, 2002; 16(3): 248 - 260. [Abstract] [PDF]
|
|